In vitro methods to study the interplay of drug metabolism and efflux in the intestine

Current Drug Metabolism

Volumn 14, Issue 1, 2013, Pages 102-111

  Siissalo, Sanna ^a   Heikkinen, Aki T ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Absorption pharmacokinetics; Drug metabolism; Efflux transporters; Efflux metabolism interplay; In vitro methods; Intestinal absorption

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CYCLOSPORIN A; CYTOCHROME P450 3A; DRUG METABOLITE; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN;

ACTIVE TRANSPORT; ARTICLE; CELL CULTURE; CELL FRACTIONATION; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG METABOLISM; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME SUBSTRATE; EPITHELIUM CELL; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; INTESTINE ABSORPTION; INTESTINE CELL; NONHUMAN; PROTEIN EXPRESSION;

EID: 84871343948     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920013804545241     Document Type: Article

References (101)

1. Wang, J.; Urban L.; Bojanic D. Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety. Expert Opin. Drug Metab. Toxicol., 2007, 3, 641-65.
2. Kaminsky, L. S.; Zhang Q. Y. The small intestine as a xenobioticmetabolizing organ. Drug Metab. Dispos., 2003, 31, 1520-5.
3. Oostendorp, R. L.; Beijnen J. H.; Schellens J. H. The biological and clinical role of drug transporters at the intestinal barrier. Cancer Treat. Rev., 2009, 35, 137-47.
4. Shugarts, S.; Benet L. Z. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm. Res., 2009, 26, 2039-54.
5. Chan, L. M.; Lowes S.; Hirst B. H. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci., 2004, 21, 25-51.
6. Thelen, K.; Dressman J. B. Cytochrome P450-mediated metabolism in the human gut wall. J. Pharm. Pharmacol., 2009, 61, 541-558.
7. Mizuma, T.; Kawashima K.; Sakai S.; Sakaguchi S.; Hayashi M. Differentiation of organ availability by sequential and simultaneous analyses: intestinal conjugative metabolism impacts on intestinal availability in humans. J. Pharm. Sci., 2005, 94, 571-5.
8. Back, D. J.; Rogers S. M. Review: first-pass metabolism by the gastrointestinal mucosa. Aliment. Pharmacol. Ther., 1987, 1, 339-57.
9. Zhang, L.; Zhang Y. D.; Strong J. M.; Reynolds K. S.; Huang S. M. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica, 2008, 38, 709-24.
10. Christians, U.; Schmitz V.; Haschke M. Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin. Drug Metab. Toxicol., 2005, 1, 641-54.
11. Huang, S. M.; Strong J. M.; Zhang L.; Reynolds K. S.; Nallani S.; Temple R.; Abraham S.; Habet S. A.; Baweja R. K.; Burckart G. J.; Chung S.; Colangelo P.; Frucht D.; Green M. D.; Hepp P.; Karnaukhova E.; Ko H. S.; Lee J. I.; Marroum P. J.; Norden J. M.; Qiu W.; Rahman A.; Sobel S.; Stifano T.; Thummel K.; Wei X. X.; Yasuda S.; Zheng J. H.; Zhao H.; Lesko L. J. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol., 2008, 48, 662-70.
12. Gertz, M.; Houston J. B.; Galetin A. Physiologically-based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab. Dispos., 2011, 39(9), 1633-42.
13. Kadono, K.; Akabane T.; Tabata K.; Gato K.; Terashita S.; Teramura T. Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor. Drug Metab. Dispos., 2010, 38, 1230-7.
14. Murakami, T.; Takano M. Intestinal efflux transporters and drug absorption. Expert Opin. Drug Metab. Toxicol., 2008, 4, 923-39.
15. Benet, L. Z.; Broccatelli F.; Oprea T. I. BDDCS applied to over 900 drugs. Aaps. J., 2011, 13, 519-47.
16. Wu, C. Y.; Benet L. Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res., 2005, 22, 11-23.
17. Poulin, P.; Jones H. M.; Jones R. D.; Yates J. W. T.; Gibson C. R.; Chien J. Y.; Ring B. J.; Adkison K. K.; He H.; Vuppugalla R.; Marathe P.; Fischer V.; Dutta S.; Sinha V. K.; Björnsson T.; Lavé T.; Ku M. S. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: Goals, properties of the PhRMA dataset, and comparison with literature datasets. J. Pharm. Sci., 2011, 100, 4050-4073.
18. Cao, X.; Gibbs S. T.; Fang L.; Miller H. A.; Landowski C. P.; Shin H. C.; Lennernas H.; Zhong Y.; Amidon G. L.; Yu L. X.; Sun D. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res., 2006, 23, 1675-86.
19. Parrott, N.; Davies B.; Hoffmann G.; Koerner A.; Lave T.; Prinssen E.; Theogaraj E.; Singer T. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. Clin. Pharmacokinet., 2011, 50, 613-23.
20. Jones, H. M.; Dickins M.; Youdim K.; Gosset J. R.; Attkins N. J.; Hay T. L.; Gurrell I. K.; Logan Y. R.; Bungay P. J.; Jones B. C.; Gardner I. B. Application of PBPK modelling in drug discovery and development at Pfizer. Xenobiotica, 2012, 42, 94-106.
21. van Waterschoot, R. A.; Schinkel A. H. A Critical Analysis of the Interplay between Cytochrome P450 3A and P-Glycoprotein: Recent Insights from Knockout and Transgenic Mice. Pharmacol. Rev., 2011, 63, 390-410.
22. Mudra, D. R.; Desai P. V.; Desino K. E. In silico, In vitro and In situ Models to Assess Interplay Between CYP3A and P-gp. Curr. Drug Metab., 2011, 12, 750-73.
23. Cummins, C. L.; Jacobsen W.; Christians U.; Benet L. Z. CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J. Pharmacol. Exp. Ther., 2004, 308, 143-55.
24. Cummins, C. L.; Salphati L.; Reid M. J.; Benet L. Z. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J. Pharmacol. Exp. Ther., 2003, 305, 306-14.
25. Benet, L. Z. The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol. Pharm., 2009, 6, 1631-43.
26. Wu, B. Pharmacokinetic interplay of phase II metabolism and transport: A theoretical study. J. Pharm. Sci., 2011.
27. Kosaka, K.; Sakai N.; Endo Y.; Fukuhara Y.; Tsuda-Tsukimoto M.; Ohtsuka T.; Kino I.; Tanimoto T.; Takeba N.; Takahashi M.; Kume T. Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene. Drug Metab. Dispos., 2011, 39, 1495-502.
28. Jeong, E. J.; Liu X.; Jia X.; Chen J.; Hu M. Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions. Curr. Drug Metab., 2005, 6, 455-68.
29. Fujiwara, R.; Nakajima M.; Yamanaka H.; Katoh M.; Yokoi T. Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates. Drug Metab. Dispos., 2008, 36, 361-7.
30. Uchaipichat, V.; Mackenzie P. I.; Guo X. H.; Gardner-Stephen D.; Galetin A.; Houston J. B.; Miners J. O. Human udpglucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab. Dispos., 2004, 32, 413-23.
31. Siissalo, S.; Laine L.; Tolonen A.; Kaukonen A. M.; Finel M.; Hirvonen J. Caco-2 cell monolayers as a tool to study simultaneous phase II metabolism and metabolite efflux of indomethacin, paracetamol and 1-naphthol. Int. J. Pharm., 2010, 383, 24-29.
32. Trdan Lusin, T.; Trontelj J.; Mrhar A. Raloxifene Glucuronidation in Human Intestine, Kidney and Liver Microsomes and in Human Liver Microsomes Genotyped for the UGT1A1*28 Polymorphism. Drug Metab. Dispos., 2011. [Epub ahead of Print].
33. Berginc, K.; Trdan T.; Trontelj J.; Kristl A. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy. Biopharm Drug Dispos., 2010, 31, 495-505.
34. Zhang, Z.; Li Y.; Shou M.; Zhang Y.; Ngui J. S.; Stearns R. A.; Evans D. C.; Baillie T. A.; Tang W. Influence of different recombinant systems on the cooperativity exhibited by cytochrome P4503A4. Xenobiotica, 2004, 34, 473-86.
35. Patten, C. J. New technologies for assessing UDP-glucuronosyltransferase (UGT) metabolism in drug discovery and development. Drug Discov. Today Technol, 2006, 3, 73-78.
36. Venkatakrishnan, K.; von Moltke L. L.; Court M. H.; Harmatz J. S.; Crespi C. L.; Greenblatt D. J. Comparison between Cytochrome P450 (CYP) Content and Relative Activity Approaches to Scaling from cDNA-Expressed CYPs to Human Liver Microsomes: Ratios of Accessory Proteins as Sources of Discrepancies between the Approaches. Drug Metab. Dispos., 2000, 28, 1493-1504.
37. Remmel, R. P.; Burchell B. Validation and use of cloned, expressed human drug-metabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions. Biochem. Pharmacol, 1993, 46, 559-566.
38. Proctor, N. J.; Tucker G. T.; Rostami-Hodjegan A. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica, 2004, 34, 151-78.
39. Paine, M. F.; Khalighi M.; Fisher J. M.; Shen D. D.; Kunze K. L.; Marsh C. L.; Perkins J. D.; Thummel K. E. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther., 1997, 283, 1552-1562.
40. Bruyere, A.; Decleves X.; Bouzom F.; Proust L.; Martinet M.; Walther B.; Parmentier Y. Development of an optimized procedure for the preparation of rat intestinal microsomes: comparison of hepatic and intestinal microsomal cytochrome P450 enzyme activities in two rat strains. Xenobiotica, 2009, 39, 22-32.
41. Galetin, A.; Houston J. B. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of firstpass metabolism. J. Pharmacol. Exp. Ther., 2006, 318, 1220-9.
42. Wang, Q.; Ye C.; Jia R.; Owen A. J.; Hidalgo I. J.; Li J. Interspecies comparison of 7-hydroxycoumarin glucuronidation and sulfation in liver S9 fractions. In vitro Cell Dev. Biol. Anim., 2006, 42, 8-12.
43. Tucker, G. T.; Houston J. B.; Huang S. M. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharm. Res., 2001, 18, 1071-80.
44. Doige, C. A.; Sharom F. J. Transport properties of P-glycoprotein in plasma membrane vesicles from multidrug-resistant Chinese hamster ovary cells. Biochim. Biophys. Acta., 1992, 1109, 161-71.
45. Sarkadi, B.; Price E. M.; Boucher R. C.; Germann U. A.; Scarborough G. A. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J. Biol. Chem., 1992, 267, 4854-4858.
46. Polli, J. W.; Wring S. A.; Humphreys J. E.; Huang L.; Morgan J. B.; Webster L. O.; Serabjit-Singh C. S. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther., 2001, 299, 620-628.
47. Giacomini, K. M.; Huang S. M.; Tweedie D. J.; Benet L. Z.; Brouwer K. L.; Chu X.; Dahlin A.; Evers R.; Fischer V.; Hillgren K. M.; Hoffmaster K. A.; Ishikawa T.; Keppler D.; Kim R. B.; Lee C. A.; Niemi M.; Polli J. W.; Sugiyama Y.; Swaan P. W.; Ware J. A.; Wright S. H.; Wah Yee S.; Zamek-Gliszczynski M. J.; Zhang L. Membrane transporters in drug development. Nat. Rev. Drug Discov., 2010, 9, 215-236.
48. Glavinas, H.; Mehn D.; Jani M.; Oosterhuis B.; Heredi-Szabo K.; Krajcsi P. Utilization of membrane vesicle preparations to study drug-ABC transporter interactions. Expert Opin. Drug Metab. Toxicol., 2008, 4, 721-732.
49. Miliotis, T.; Ali L.; Palm J. E.; Lundqvist A. J.; Ahnoff M.; Andersson T. B.; Hilgendorf C. Development of a Highly Sensitive Method using LC-MRM to Quantify Membrane P-glycoprotein in Biological Matrices and Relationship to Transport Function. Drug Metab. Dispos., 2011, 39, 2440-2449.
50. Kuteykin-Teplyakov, K.; Luna-Tortos C.; Ambroziak K.; Loscher W. Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport. Br. J. Pharmacol., 2010, 160, 1453-63.
51. Cui, Y.; Konig J.; Buchholz J. K.; Spring H.; Leier I.; Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol., 1999, 55, 929-37.
52. Pastan, I.; Gottesman M. M.; Ueda K.; Lovelace E.; Rutherford A. V.; Willingham M. C. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc. Nat. Acad. Sci. USA, 1988, 85, 4486-90.
53. Adachi, Y.; Suzuki H.; Sugiyama Y. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm. Res., 2001, 18, 1660-1668.
54. Zeng, H.; Bain L. J.; Belinsky M. G.; Kruh G. D. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res., 1999, 59, 5964-7.
55. Kamau, S.; Krämer S.; Günthert M.; Wunderli-Allenspach H. Effect of the modulation of the membrane lipid composition on the localization and function of P-glycoprotein in MDR1-MDCK cells. In vitro Cell Dev. Biol. Anim., 2005, 41, 207-216.
56. Audus, K. L.; Bartel R. L.; Hidalgo I. J.; Borchardt R. T. Thse use of cultured epithelial and endothelial cells for drug transport and metabolism studies. Pharm. Res., 1990, 7, 435-51.
57. Hubatsch, I.; Ragnarsson E. G.; Artursson P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat. Protoc., 2007, 2, 2111-2119.
58. Seithel, A.; Karlsson J.; Hilgendorf C.; Bjorquist A.; Ungell A. L. Variability in mRNA expression of ABC-and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. Eur. J. Pharm. Sci., 2006, 28, 291-299.
59. Siissalo, S.; Zhang H.; Stilgenbauer E.; Kaukonen A. M.; Hirvonen J.; Finel M. The expression of most UDP-glucuronosyltransferases (UGTs) is increased significantly during Caco-2 cell differentiation, whereas UGT1A6 is highly expressed also in undifferentiated cells. Drug Metab. Dispos., 2008, 36, 2331-6.
60. Sun, D.; Lennernas H.; Welage L. S.; Barnett J. L.; Landowski C. P.; Foster D.; Fleisher D.; Lee K. D.; Amidon G. L. Comparison of human duodenum and Caco-2 gene expression profiles for 12, 000 gene sequences tags and correlation with permeability of 26 drugs. Pharm. Res., 2002, 19, 1400-16.
61. Meinl, W.; Ebert B.; Glatt H.; Lampen A. Sulfotransferase forms expressed in human intestinal Caco-2 and TC7 cells at varying stages of differentiation and role in benzo [a]pyrene metabolism. Drug Metab. Dispos., 2008, 36, 276-83.
62. Sambuy, Y.; De Angelis I.; Ranaldi G.; Scarino M. L.; Stammati A.; Zucco F. The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol. Toxicol., 2005, 21, 1-26.
63. Schmiedlin-Ren, P.; Thummel K. E.; Fisher J. M.; Paine M. F.; Lown K. S.; Watkins P. B. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha, 25-dihydroxyvitamin D3. Mol. Pharmacol., 1997, 51, 741-54.
64. Korjamo, T.; Mönkkönen J.; Uusitalo J.; Turpeinen M.; Pelkonen O.; Honkakoski P. Metabolic and efflux properties of Caco-2 cells stably transfected with nuclear receptors. Pharm. Res., 2006, 23, 1991-2001.
65. Korjamo, T.; Honkakoski P.; Toppinen M. R.; Niva S.; Reinisalo M.; Palmgren J. J.; Mönkkönen J. Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines. Eur. J. Pharm. Sci., 2005, 26, 266-279.
66. Hayeshi, R.; Hilgendorf C.; Artursson P.; Augustijns P.; Brodin B.; Dehertogh P.; Fisher K.; Fossati L.; Hovenkamp E.; Korjamo T.; Masungi C.; Maubon N.; Mols R.; Mullertz A.; Monkkonen J.; O'Driscoll C.; Oppers-Tiemissen H. M.; Ragnarsson E. G.; Rooseboom M.; Ungell A. L. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur. J. Pharm. Sci., 2008, 35, 383-396.
67. Bonnefille, P.; Sezgin-Bayindir Z.; Belkhelfa H.; Arellano C.; Gandia P.; Woodley J.; Houin G. The use of isolated enterocytes to study Phase I intestinal drug metabolism: validation with rat and pig intestine. Fundam. Clin. Pharmacol., 2011, 25, 104-14.
68. Glaeser, H.; Drescher S.; van der Kuip H.; Behrens C.; Geick A.; Burk O.; Dent J.; Somogyi A.; Von Richter O.; Griese E. U.; Eichelbaum M.; Fromm M. F. Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters. Clin. Pharmacol. Ther., 2002, 71, 131-40.
69. Grossmann, J.; Walther K.; Artinger M.; Kiessling S.; Steinkamp M.; Schmautz W. K.; Stadler F.; Bataille F.; Schultz M.; Scholmerich J.; Rogler G. Progress on isolation and short-term exvivo culture of highly purified non-apoptotic human intestinal epithelial cells (IEC). Eur. J. Cell Biol., 2003, 82, 262-70.
70. Spence, J. R.; Mayhew C. N.; Rankin S. A.; Kuhar M. F.; Vallance J. E.; Tolle K.; Hoskins E. E.; Kalinichenko V. V.; Wells S. I.; Zorn A. M.; Shroyer N. F.; Wells J. M. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature, 2011, 470, 105-9.
71. Konsoula, R.; Barile F. A. Correlation of in vitro cytotoxicity with paracellular permeability in Caco-2 cells. Toxicol. In vitro, 2005, 19, 675-84.
72. Siissalo, S.; Hannukainen J.; Kolehmainen J.; Hirvonen J.; Kaukonen A. M. A Caco-2 cell based screening method for compounds interacting with MRP2 efflux protein. Eur. J. Pharm. Biopharm., 2009, 71, 332-8.
73. Zhang, Y.; Bachmeier C.; Miller D. W. In vitro and in vivo models for assessing drug efflux transporter activity. Adv. Drug Deliv. Rev., 2003, 55, 31-51.
74. Ho, N. F.; Burton P. S.; Conradi R. A.; Barsuhn C. L. A biophysical model of passive and polarized active transport processes in Caco-2 cells: approaches to uncoupling apical and basolateral membrane events in the intact cell. J. Pharm. Sci., 1995, 84, 21-27.
75. Sun, H.; Chow E. C.; Liu S.; Du Y.; Pang K. S. The Caco-2 cell monolayer: usefulness and limitations. Expert Opin. Drug Metab. Toxicol., 2008, 4, 395-411.
76. Haslam, I. S.; O'Reilly D. A.; Sherlock D. J.; Kauser A.; Womack C.; Coleman T. Pancreatoduodenectomy as a source of human small intestine for Ussing chamber investigations and comparative studies with rat tissue. Biopharm. Drug Dispos., 2011, 32, 210-21.
77. Browning, T. H.; Trier J. S. Organ culture of mucosal biopsies of human small intestine. J. Clin. Invest., 1969, 48, 1423-32.
78. van de Kerkhof, E. G.; de Graaf I. A.; Groothuis G. M. In vitro methods to study intestinal drug metabolism. Curr. Drug Metab., 2007, 8, 658-75.
79. Wilson, T. H.; Wiseman G. The use of sacs of everted small intestine for the study of the transference of substances from the mucosal to the serosal surface. J. Physiol., 1954, 123, 116-25.
80. van de Kerkhof, E. G.; Ungell A. L.; Sjoberg A. K.; de Jager M. H.; Hilgendorf C.; de Graaf I. A.; Groothuis G. M. Innovative methods to study human intestinal drug metabolism in vitro: precision-cut slices compared with ussing chamber preparations. Drug Metab. Dispos., 2006, 34, 1893-902.
81. van de Kerkhof, E. G.; de Graaf I. A. M.; Ungell A.-L. B.; Groothuis G. M. M. Induction of Metabolism and Transport in Human Intestine: Validation of Precision-Cut Slices as a Tool to Study Induction of Drug Metabolism in Human Intestine in vitro. Drug Metab. Dispos., 2008, 36, 604-613.
82. Pelkonen, O.; Turpeinen M.; Raunio H. In vivo-In vitro-In Silico Pharmacokinetic Modelling in Drug Development: Current Status and Future Directions. Clin. Pharmacokinet., 2011, 50, 483-491.
83. Gertz, M.; Harrison A.; Houston J. B.; Galetin A. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab. Dispos., 2010, 38, 1147-58.
84. Yang, J.; Jamei M.; Yeo K. R.; Tucker G. T.; Rostami-Hodjegan A. Prediction of intestinal first-pass drug metabolism. Curr. Drug Metab., 2007, 8, 676-684.
85. Nishimuta, H.; Sato K.; Yabuki M.; Komuro S. Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data. Drug Metab. Pharmacokinet., 2011, 26(6), 592-601.
86. Del Amo, E. M.; Heikkinen A. T.; Mönkkönen J. In vitro-in vivo correlation in p-glycoprotein mediated transport in intestinal absorption. Eur. J. Pharm. Sci., 2009, 36, 200-211.
87. Bolger, M. B.; Lukacova V.; Woltosz W. S. Simulations of the Nonlinear Dose Dependence for Substrates of Influx and Efflux Transporters in the Human Intestine. AAPS. J., 2009, 11, 353-363.
88. Fenneteau, F.; Poulin P.; Nekka F. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. J. Pharm. Sci., 2010, 99, 486-514.
89. Barter, Z. E.; Bayliss M. K.; Beaune P. H.; Boobis A. R.; Carlile D. J.; Edwards R. J.; Houston J. B.; Lake B. G.; Lipscomb J. C.; Pelkonen O. R.; Tucker G. T.; Rostami-Hodjegan A. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Metab., 2007, 8, 33-45.
90. Kamiie, J.; Ohtsuki S.; Iwase R.; Ohmine K.; Katsukura Y.; Yanai K.; Sekine Y.; Uchida Y.; Ito S.; Terasaki T. Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm. Res., 2008, 25, 1469-83.
91. Kawakami, H.; Ohtsuki S.; Kamiie J.; Suzuki T.; Abe T.; Terasaki T. Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection. J. Pharm. Sci., 2010, 100, 341-52.
92. Uchida, Y.; Ohtsuki S.; Kamiie J.; Terasaki T. Blood-Brain Barrier (BBB) Pharmacoproteomics (PPx): Reconstruction of In vivo Brain Distribution of 11 P-glycoprotein Substrates based on the BBB Transporter Protein Concentration, In vitro Intrinsic Transport Activity, and Unbound Fraction in Plasma and Brain in Mice. J. Pharmacol. Exp. Ther., 2011. [Epub ahead of Print].
93. Hallifax, D.; Foster J. A.; Houston J. B. Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm. Res., 2010, 27, 2150-61.
94. Heikkinen, A. T.; Korjamo T.; Lepikkö V.; Mönkkönen J. Effects of Experimental Setup on the Apparent Concentration Dependency of Active Efflux Transport in in vitro Cell Permeation Experiments. Mol. Pharm., 2010, 7, 605-617.
95. Matsson, P.; Bergstrom C. A.; Nagahara N.; Tavelin S.; Norinder U.; Artursson P. Exploring the role of different drug transport routes in permeability screening. J Med Chem 2005, 48, 604-613.
96. Sun, H.; Zhang L.; Chow E. C.; Lin G.; Zuo Z.; Pang K. S. A catenary model to study transport and conjugation of baicalein, a bioactive flavonoid, in the Caco-2 cell monolayer: demonstration of substrate inhibition. J. Pharmacol. Exp. Ther., 2008, 326, 117-126.
97. Bentz, J.; Tran T. T.; Polli J. W.; Ayrton A.; Ellens H. The steadystate Michaelis-Menten analysis of P-glycoprotein mediated transport through a confluent cell monolayer cannot predict the correct Michaelis constant Km. Pharm. Res., 2005, 22, 1667-1677.
98. Heikkinen, A. T.; Korjamo T.; Mönkkönen J. Modelling of Drug Disposition Kinetics in In vitro Intestinal Absorption Cell Models. Basic Clin. Pharmacol. Toxicol., 2010, 106, 180-188.
99. Poirier, A.; Funk C.; Scherrmann J. M.; Lave T. Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine. Mol. Pharm., 2009, 6, 1716-33.
100. Tavelin, S.; Taipalensuu J.; Soderberg L.; Morrison R.; Chong S.; Artursson P. Prediction of the oral absorption of low-permeability drugs using small intestine-like 2/4/A1 cell monolayers. Pharm. Res., 2003, 20, 397-405.
101. de Graaf, I. A.; Olinga P.; de Jager M. H.; Merema M. T.; de Kanter R.; van de Kerkhof E. G.; Groothuis G. M. Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. Nat. Protoc., 2010, 5, 1540-51.